Results 51 to 60 of about 427,680 (294)

Branch Retinal Vein Occlusion [PDF]

The Journal of Clinical Hypertension, 2003
The most common cause of branch retinal vein occlusion is hypertension. Since retinal arteries and veins share a common adventitial sheath, the thickened artery compresses a retinal vein causing an occlusion, resulting in a retinal hemorrhage. Most patients present in their 60s with unilateral involvement. The patient may be asymptomatic if the macula
Milan R, Patel, L Michael, Prisant, Dennis M, Marcus   +2 more
openaire   +2 more sources

Intelligent Micro/Nanorobots for Targeted Interventional Therapy: From Bench to Clinic

Advanced Robotics Research, EarlyView.
Zirui Zhang et al. reviewed the application and challenges of mobile nanomachines in interventional therapy. By converting exogenous energy, including chemical, magnetic, optical, and ultrasonic sources, into mechanical forces, micro/nanorobots (MNRs) enable precise actuation at unprecedented scales. Evolving far beyond traditional drug delivery, these
Zirui Zhang, Yu Dong, Yongsheng Du, Rui Gao, Lin Zhang, Fei Tong   +5 more
wiley   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

BILATERAL SIMULTANEOUS CENTRAL RETINAL VEIN OCCLUSION IN A PATIENT WITH SYSTEMIC HYPERTENSION

Journal of University Medical & Dental College, 2020
The central retinal vein occlusion is caused by age related changes in the retinal vessels. Bilateral central retinal vein occlusion is a relatively rare event. Only less than 10% cases are bilateral.
Basim Mubarik, Aamir Ali Choudhry
doaj  

[Retinal vein occlusion: Therapy of retinal vein occlusion].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2016
Treatment of retinal vein occlusion can be systemic or local. Therapeutic strategies include improved blood supply, treatment of the vision-reducing macular edema by intravitreal injection of inhibitors of vascular endothelial growth factors (VEGF) or corticosteroids and laser photocoagulation for neovascular complications.
Feltgen, Nicolas, Pielen, A.
openaire   +2 more sources

Retinal vein occlusion.

Indian journal of ophthalmology, 1994
In this review of the retinal vein occlusion (RVO), I have summarized recent advances on several controversial and clinically important topics: classification of RVO into six distinct clinical entities; pathogeneses and demographic characteristics of various types of RVO; differentiation of non-ischemic from ischemic central retinal vein occlusion ...
openaire   +3 more sources

Central Retinal Vein Occlusion Following Intravenous Immunoglobulin Treatment in a Patient with Pemphigus Vulgaris

, 2017
A 68-year-old male has been treated with prednisolone and intravenous immunoglobulin (IVIG) therapies with the diagnosis of pemphigus vulgaris. When he applied to receive the fifth session of IVIG therapy, he complained about visual loss.
Müge Pınar Özdal, Aysun Șanal Doğan, Müzeyyen Gönül, Damla Atacan   +3 more
core   +1 more source

GHRHR Deficiency Enhances Retinal Ganglion Cell Survival and Visual Functions in Experimental Glaucoma by Inhibiting Ferroptosis

Advanced Science, EarlyView.
Glaucoma, a major cause of blindness, involves retinal ganglion cell (RGC) degeneration. This study shows growth hormone‐releasing hormone receptor (GHRHR) deficiency preserves RGC survival and restores vision, unlike activation which only aids survival.
Yan Tong, Ming Ho Yam, Jiaxin Zhang, Lin Du, Linbin Zhou, Yolanda Wong Ying Yip, Bo Man Ho, Hemlata Bisnauthsing, Jiahui Li, Ivan Kong, Shushu Xu, Changzhen Fu, Karl K.H. So, Joaquim S.L. Vong, Ling‐Ping Cen, Ming‐Ming Yang, Khazeema Yousaf, Mai Har Sham, Sun On Chan, Poemen P. Chan, Chi Pui Pang, Clement C. Tham, Jing Na He, Jian Li, Wai Kit Chu   +24 more
wiley   +1 more source

An Aggregation‐Induced Polymerization Poly(Disulfide)‐Drug Nanoplatform for Autoimmune Uveitis Therapy via Inhibiting the cGAS‐STING Pathway

Advanced Science, EarlyView.
A cationic poly(disulfide)‐drug nanoplatform (LA/DexP) was developed to treat experimental autoimmune uveitis (EAU). With potent blood‐retinal barrier penetrability, LA/DexP releases DSP in response to high ROS and scavenges cfDNA to inhibit the cGAS‐STING signaling pathway.
Yuelan Wu, Wenbo Geng, Qinjin Dai, Wanyun Zhang, Yuxian Lai, Pei Zhang, Chunjiang Zhou, Yinuo Wang, Qingfeng Cao, Xiang Luo, Yujie Lai, Changwei Huang, Peizeng Yang   +12 more
wiley   +1 more source

Case series of branch retinal vein occlusion secondary to rhegmatogenous retinal detachment and its surgical management

BMC Ophthalmology, 2023
Background To review cases of branch retinal vein occlusion (BRVO) secondary to rhegmatogenous retinal detachment (RRD) and its surgical management and presume their mechanism.
Youna Choi, Sung Jun Kim, Jae Jung Lee, Moosa Hasan Zaidi, Yong Un Shin, Ik Soo Byon, Ji Eun Lee, Sung Who Park   +7 more
doaj   +1 more source